NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Myriad Genetics' BRACAnalysis CDx as a complementary diagnostic to identify ovarian cancer patients with germline BRCA mutations who are likely to benefit most from treatment with Zejula (niraparib).
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.